IMI offers €12.2m for better ways of testing effectiveness of flu vaccines
This article was originally published in Scrip
Executive Summary
€12.2m in EU funding is being made available for new ideas on how to develop standardised tests that can more accurately determine how effective a new influenza vaccine is likely to be. The funding is being offered by Europe's Innovative Medicines Initiative (IMI), a joint undertaking between the pharmaceutical industry federation EFPIA and the European Commission.